Scientists take different approaches to same goal


Daria Hazuda, Merck's vice president of infectious disease and vaccine discovery research, is working with Ridgeback Therapeutics on a treatment for COVID-19 called molnupiravir, which targets a stable part of SARS-CoV-2 to prevent resistance. Adolfo Garcia-Sastre, director of Mount Sinai's Global Health and Emerging Pathogens Institute, has taken a different approach to the same goal with a multiple myeloma drug called plitidepsin that prevents the virus from hijacking human proteins to replicate.

Full story:

FasterCures SmartBrief

News that examines speeding discovery and development of new therapies by looking at issues in science and technology, law and regulation, economics and finance, and society and ethics.

Designed specifically for those in pursuit of medical solutions, FasterCures SmartBrief is a FREE twice-weekly newsletter. Providing targeted news from hundreds of top industry sources, FasterCures SmartBrief keeps you informed about important medical solutions news.